Evidence map›Paper›PMID 40197185›Full record

ReviewCurrent neuropharmacology2025

The Multifaceted Role of Neuroprotectin D1: Physiological, Pathophysiological, and Pharmacological Insights in Neurodegenerative Diseases.

Bushra Zia, Mariam Elmeky, Sheikh Azimullah, Niraj Kumar Jha, Mohamed Fizur Nagoor Meeran, Shreesh K Ojha

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bushra ZiaDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 15551, Al Ain, UAE.
Mariam ElmekyDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 15551, Al Ain, UAE.
Sheikh AzimullahDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 15551, Al Ain, UAE.
Niraj Kumar JhaSchool of Bioengineering & Biosciences, Lovely Professional University, Phagwara, 144411, Punjab, India.
Mohamed Fizur Nagoor MeeranDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 15551, Al Ain, UAE.
Shreesh K OjhaDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO Box: 15551, Al Ain, UAE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroprotectin D1 (NPD1) has emerged as an integral lipid mediator with significant implications for maintaining neurological health. Being derived from docosahexaenoic acid (DHA), NPD1 is a specialized pro-resolving lipid mediator (SPM), consisting of a unique structure that attributes potent anti-inflammatory and neuroprotective properties crucial for maintaining nervous system homeostasis. It exerts its actions through diverse mechanisms, including the inhibition of proinflammatory cytokines, modulation of apoptosis, and promotion of cellular survival pathways. The dysregulation or deficiency of NPD1 has been implicated in the onset and progression of several neurodegenerative diseases, such as Alzheimer's, Parkinson's, and stroke, underscoring its critical role in maintaining neuronal health and disease prevention. Abnormal NPD1 signalling is associated with neuroinflammation, oxidative stress, and neuronal apoptosis, which in turn contribute significantly to the progression of neurological disorders. Understanding these pathways offers insights into potential therapeutic strategies aimed at targeting NPD1 to mitigate neurodegenerative processes and facilitate neural repair. The efforts in developing NPD1 analogs or mimetics are focused on enhancing endogenous NPD1 levels, attenuating neuroinflammation, and preserving neuronal integrity in disease contexts. This review provides a comprehensive exploration of NPD1, encompassing its structural characteristics, biochemical pathways, physiological roles, pathophysiological implications, and potential therapeutic applications in neurological disorders. Further, research into elucidating the precise mechanisms of NPD1 reveals that its clinical efficacy is crucial for harnessing its full potential as a therapeutic tool for neuroprotection and neural repair.

Indexed as

Docosahexaenoic AcidsNeurodegenerative DiseasesNeuroprotective AgentsAnimalsHumansDocosahexaenoic AcidsNeuroprotective Agentsprotectin D1Cyclooxygenasesdocosahexaenoic acidinflammatory cytokineslipoxygenasesneurodegenerative diseasesNeuroprotectin D1neuroprotectivepro-resolving lipid mediators.protectin D

Identifiers

PMID40197185
PMCPMC12308007

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.